News

The acquisition is in accordance with the development, option and stock purchase agreement (DOSPA) entered by Fortress Biotech, Caelum, Alexion and others. Biopharmaceutical company Fortress founded Caelum, which

AZD7442 is a cocktail of two long-acting antibodies — tixagevimab (AZD8895) and cilgavimab (AZD1061). The US Vanderbilt University Medical Center-discovered LAAB combination was licenced to AstraZeneca in June last year.

An experimental product candidate, ACER-001 is being developed to treat several inborn errors of metabolism, such as UCDs and maple syrup urine disease (MSUD). The application to the

Being trialled in the US, this drug is yet to gain approval from the regulatory authorities. The federal government of Australia has signed an agreement with pharma firm

Kite, a subsidiary of Gilead Sciences, has received the US Food and Drug Administration (FDA) approval for its Tecartus (brexucabtagene autoleucel) to treat patients with relapsed or refractory

As agreed, Merck’s subsidiary will commence a tender offer for the purchase of shares of Acceleron for $180 per share. Following completion of deal, this subsidiary of Merck

TRV027 is being evaluated as a potential therapy for treating acute lung injury that leads to acute respiratory distress syndrome (ARDS) and abnormal blood clotting in patients suffering

AstraZeneca’s subsidiary Alexion has announced plans to acquire all the remaining equity stake in Caelum Biosciences for up to $500m. Alexion had entered into a partnership with Caelum

Appili Therapeutics has announced a strategic alliance with AiPharma to advance the global development of Avigan/Reeqonus (favipiravir). Avigan/Reeqonus is a broad-spectrum oral antiviral, which is currently being assessed